Taysha Gene Therapies Inc
NASDAQ:TSHA
Taysha Gene Therapies Inc
Revenue
Taysha Gene Therapies Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
Revenue
$8.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$33.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Taysha Gene Therapies Inc
Glance View
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 178 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.
See Also
What is Taysha Gene Therapies Inc's Revenue?
Revenue
8.3m
USD
Based on the financial report for Dec 31, 2024, Taysha Gene Therapies Inc's Revenue amounts to 8.3m USD.
What is Taysha Gene Therapies Inc's Revenue growth rate?
Revenue CAGR 1Y
-46%
Over the last year, the Revenue growth was -46%.
You don't have any saved screeners yet